Suppr超能文献

抗病毒多金属氧酸盐在大鼠体内的药代动力学

Pharmacokinetics of antiviral polyoxometalates in rats.

作者信息

Ni L, Boudinot F D, Boudinot S G, Henson G W, Bossard G E, Martellucci S A, Ash P W, Fricker S P, Darkes M C, Theobald B R

机构信息

Department of Pharmaceutics, College of Pharmacy, University of Georgia, Athens 30602.

出版信息

Antimicrob Agents Chemother. 1994 Mar;38(3):504-10. doi: 10.1128/AAC.38.3.504.

Abstract

Polyoxometalates are soluble mineral compounds formed principally of oxide anions and early transition metal cations. The polyoxometalates K12H2[P2W12O48].24H2O (JM 1591), K10[P2W18Zn4(H2O)2O68].20H2O (JM 1596), and [(CH3)3NH]8[Si2W18Nb6O77] (JM 2820) demonstrate potent antiviral activity against human immunodeficiency virus types 1 and 2, herpes simplex virus, and cytomegalovirus in vitro. The preclinical pharmacokinetics of these three compounds were characterized after single-dose intravenous administration of 50 mg/kg to rats. Plasma, urine, and feces were collected for 168 h, and polyoxometalate concentrations were determined by atomic emission. Serum protein binding was measured by equilibrium dialysis. All three compounds were highly bound to serum proteins in a concentration-dependent manner. Total and unbound concentrations of the three compounds in plasma declined in a triexponential manner with terminal half-lives of 246.0 +/- 127.0, 438.4 +/- 129.4, and 32.2 +/- 5.37 h (mean +/- standard deviation) for JM 1591, JM 1596, and JM 2820, respectively. Systemic clearances based on total concentrations in plasma were low, averaging 0.016 +/- 0.002, 0.015 +/- 0.002, and 0.018 +/- 0.003 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively. The clearances of unbound compounds from plasma averaged 0.966 +/- 0.136, 0.050 +/- 0.005, and 0.901 +/- 0.165 liter/h/kg for JM 1591, JM 1596, and JM 2820, respectively. For JM 1596, the clearance of unbound compound from the kidneys was lower than the glomerular filtration rate (0.086 liter/h/kg), suggesting this polyoxometalate underwent renal tubular reabsorption. However, JM 1591 and JM 2820 appeared to undergo tubular secretion. The fraction of the dose recovered in urine was 11.5, 46.8, and 10.6% for JM 1591, JM 1596, and JM 2820, respectively. Approximately 5% of the dose of each polyoxometalate was recovered in feces. The steady-state volume of distribution based on total concentrations averaged 1.44 liters/kg for JM 1591, 2.39 liters/kg for JM 1596, and 0.59 liter/kg for JM 2820, indicating moderate to wide distribution throughout the body. All three compounds were detected in various tissues 1 week after single-dose administrations, with the highest levels found in the kidneys and liver. The results of this study indicate that the disposition of polyoxometalates is highly dependent on their molecular structure.

摘要

多金属氧酸盐是主要由氧化物阴离子和早期过渡金属阳离子形成的可溶性矿物化合物。多金属氧酸盐K12H2[P2W12O48].24H2O(JM 1591)、K10[P2W18Zn4(H2O)2O68].20H2O(JM 1596)和[(CH3)3NH]8[Si2W18Nb6O77](JM 2820)在体外对1型和2型人类免疫缺陷病毒、单纯疱疹病毒和巨细胞病毒显示出强大的抗病毒活性。在对大鼠单次静脉注射50 mg/kg后,对这三种化合物的临床前药代动力学进行了表征。收集血浆、尿液和粪便168小时,通过原子发射测定多金属氧酸盐浓度。通过平衡透析测量血清蛋白结合率。所有三种化合物均以浓度依赖性方式与血清蛋白高度结合。JM 1591、JM 1596和JM 2820在血浆中的总浓度和未结合浓度以三指数方式下降,终末半衰期分别为246.0±127.0、438.4±129.4和32.2±5.37小时(平均值±标准差)。基于血浆总浓度的全身清除率较低,JM 1591、JM 1596和JM 2820分别平均为0.016±0.002、0.015±0.002和0.018±0.003升/小时/千克。JM 1591、JM 1596和JM 2820从血浆中未结合化合物的清除率分别平均为0.966±0.136、0.050±0.005和0.901±0.165升/小时/千克。对于JM 1596,未结合化合物从肾脏的清除率低于肾小球滤过率(0.086升/小时/千克),表明这种多金属氧酸盐经历了肾小管重吸收。然而,JM 1591和JM 2820似乎经历了肾小管分泌。JM 1591、JM 1596和JM 2820在尿液中回收的剂量分数分别为11.5%、46.8%和10.6%。每种多金属氧酸盐约5%的剂量在粪便中回收。基于总浓度的稳态分布容积,JM 1591平均为1.44升/千克,JM 1596为2.39升/千克,JM 2820为0.59升/千克,表明在全身分布适中至广泛。单次给药1周后,在各种组织中均检测到所有三种化合物,在肾脏和肝脏中发现的水平最高。这项研究的结果表明,多金属氧酸盐的处置高度依赖于它们的分子结构。

相似文献

1
Pharmacokinetics of antiviral polyoxometalates in rats.抗病毒多金属氧酸盐在大鼠体内的药代动力学
Antimicrob Agents Chemother. 1994 Mar;38(3):504-10. doi: 10.1128/AAC.38.3.504.
2
Non-linear renal and biliary clearances of antiviral polyoxometalates in rats.
Eur J Drug Metab Pharmacokinet. 1995 Jul-Sep;20(3):209-17. doi: 10.1007/BF03189672.
4
Pharmacokinetics of anti-HBV polyoxometalate in rats.抗乙肝多金属氧酸盐在大鼠体内的药代动力学
PLoS One. 2014 Jun 12;9(6):e98292. doi: 10.1371/journal.pone.0098292. eCollection 2014.
5
Pharmacokinetics of a water-soluble fullerene in rats.水溶性富勒烯在大鼠体内的药代动力学
Antimicrob Agents Chemother. 1996 Oct;40(10):2262-5. doi: 10.1128/AAC.40.10.2262.

引用本文的文献

1
Pharmacokinetics of anti-HBV polyoxometalate in rats.抗乙肝多金属氧酸盐在大鼠体内的药代动力学
PLoS One. 2014 Jun 12;9(6):e98292. doi: 10.1371/journal.pone.0098292. eCollection 2014.
2
Non-linear renal and biliary clearances of antiviral polyoxometalates in rats.
Eur J Drug Metab Pharmacokinet. 1995 Jul-Sep;20(3):209-17. doi: 10.1007/BF03189672.

本文引用的文献

4
Plasma and tissue binding considerations in drug disposition.
Drug Metab Rev. 1983;14(3):427-65. doi: 10.3109/03602538308991396.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验